Fu C D, Jiang X T, Hu J H, Wu W
Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai.
Yao Xue Xue Bao. 1996;31(9):706-11.
Nifedipine has been incorporated into Eudragit RL microspheres by the emulsion solvent-evaporation process using an acetone/liquid paraffin system. The drug in the Eudragit RL microspheres was present in either molecular dispersion or amorphous state. The drug release profile from microspheres conformed to the Higuchi equation. The microspheres were stable under different storage conditions for six months with respect to drug content, dispersing state and release profile. The in vivo results in eight healthy volunteers showed that the relative bioavailability of the nifedipine sustained-release microspheres against commercial retard tablet as a control was 102.5%, and the microsphere formulation was bioequivalent to the retard tablet. Significant in vitro and in vivo correlation was also found for the microspheres.
硝苯地平已通过使用丙酮/液体石蜡体系的乳液溶剂蒸发法被载入到Eudragit RL微球中。Eudragit RL微球中的药物以分子分散或无定形状态存在。微球的药物释放曲线符合Higuchi方程。在不同储存条件下,微球在药物含量、分散状态和释放曲线方面六个月内保持稳定。在八名健康志愿者身上进行的体内实验结果表明,硝苯地平缓释微球相对于作为对照的市售缓释片的相对生物利用度为102.5%,且微球制剂与缓释片具有生物等效性。同时还发现微球在体外和体内具有显著的相关性。